The Board at its meeting held today i.e. May 29, 2026 have approved Early Retirement of Company Secretary & Compliance Officer, Appointment of Company Secretary & Compliance Officer and ....
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
The Board of Glenmark Pharmaceuticals approved the early retirement of Mr. Harish Kuber from the position of Company Secretary & Compliance Officer (Key Managerial Personnel), effective from the close of business hours on May 29, 2026. Mr. Kuber served the company for over nine and a half years and submitted his resignation, offering to continue for a few months for smooth transition. The Board simultaneously appointed Ms. Rashmi Khandelwal, a qualified Company Secretary with over 17 years of experience in corporate governance and regulatory matters, as the new Company Secretary & Compliance Officer effective May 30, 2026. Additionally, Mr. Samir Kazi, Executive Vice President & Head Legal, Compliance & IP, was designated as Senior Management Personnel.
The departure of the long-serving Company Secretary marks a leadership transition in the compliance function. However, the immediate appointment of a highly experienced replacement with a strong governance background may limit any negative market reaction. The filing is routine KMP change with no red flags for investors.